According to a recent study conducted by Memorial Sloan Kettering Cancer Center, rates of Clostridioides difficile infection (CDI) are higher in patients with cancer than in healthy adults. This study used patient data from 93,566 patients in the SEER-Medicare database, including both healthy patients and patients with either solid tumors or hematologic malignancies diagnosed between […]

Although clinicians and drug manufacturers have always touted the value of certain treatments, cost-effectiveness hasn’t always been an integral part of the pharma market. However, priorities have shifted in recent years and value-based pricing has begun to dominate the US pharma market. As market access shifts, pharma companies must change their business model or risk […]

At Aptitude Health, we strive to understand patterns of care that affect cancer patients not enrolled in clinical trials. We identify factors influencing prescribing habits that shape best practices and positively impact patient care. CASES Summits are regional events where approximately 60 oncologists and hematologists from large community practices, along with leading scientific experts, gather […]

Guidelines from the National Comprehensive Cancer Network (NCCN) provide the foundation for treatment of breast cancer in the United States. However, as many as 1 in 5 patients receive treatment regimens that are not recommended by the NCCN, according to a recent study published in the Journal of the National Comprehensive Cancer Network. In this […]

Pharma and biotech companies thrive on communication with key opinion leaders (KOLs). However, connecting with these individuals can be a challenge. Identifying your outreach goals helps eliminate logistic roadblocks. Once you have your organization’s goals in mind, you can seek out individuals who can help you on the path to success. Read on to learn […]

As conference season winds down, you can still squeeze value out of your conference experiences. Among the big reasons to attend a major oncology conference are the opportunities you have to make new connections and cultivate new relationships, and the chance to get a leg up on the newest information in your field. To get […]

Each year, the medical industry uncovers exciting new data that can help in the fight against cancer. However, this information isn’t always distributed effectively. Yet stakeholders desperately need access to the latest clinical data. If they aren’t able to locate these data, patients may not benefit from the new insights. Information gaps have a tremendous […]

In late August, the US Food and Drug Administration (FDA) granted priority review to the Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received one or more prior lines of therapy. Zanubrutinib had previously been given a Breakthrough Therapy designation for this indication. MCL is […]

On August 21, an application for the androgen receptor inhibitor enzalutamide was granted priority review by the United States Food and Drug Administration (FDA). Enzalutamide is currently approved for treatment of both nonmetastatic and metastatic castration-resistant prostate cancer (mCRPC). This new application adds an indication for enzalutamide as a treatment for patients with metastatic hormone-sensitive […]

Pneumonitis is emerging as an adverse event of many oncology targeted therapies, including immune checkpoint inhibitors and some tyrosine kinase inhibitors. On September 13, the US Food and Drug Administration (FDA) released an important safety communication regarding the risk of lung inflammation, including pneumonitis and interstitial lung disease, associated with another class of targeted therapies: […]